Journal article icon

Journal article

Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer.

Abstract:

BACKGROUND: A previous dose-escalation trial of the vascular disrupting agent combretastatin A4 phosphate (CA4P) given before carboplatin, paclitaxel, or both showed responses in 7 of 18 patients with relapsed ovarian cancer. PATIENTS AND METHODS: Patients with ovarian cancer that had relapsed and who could start trial therapy within 6 months of their last platinum chemotherapy were given CA4P 63 mg/m(2) minimum 18 h before paclitaxel 175 mg/m(2) and carboplatin AUC (area under the concentra...

Expand abstract
Publication status:
Published

Actions


Access Document


Publisher copy:
10.1093/annonc/mdq708

Authors


Expand authors...
Journal:
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO
Volume:
22
Issue:
9
Pages:
2036-2041
Publication date:
2011-09-05
DOI:
EISSN:
1569-8041
ISSN:
0923-7534
URN:
uuid:2b2664db-9097-4dc0-aac5-ec6b6832def6
Source identifiers:
355437
Local pid:
pubs:355437

Terms of use


Metrics


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP